Skip to main content
. 2021 Aug 26;49(1):54–63. doi: 10.1007/s00259-021-05474-1

Fig. 3.

Fig. 3

Distributions of patients to the respective extend of annual GFR-loss, following PRRT based on different radiopharmaceuticals (data for 90Y-DOTATOC and 177Lu-Dotatate are based on Ref.-17)